Oxford, UK – 5 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces that Dan Soland has been required to step down as a Non-Executive Director, due to his appointment as CEO of uniQure with immediate effect.
Commenting on the announcement, Dan Soland, said: "It is with regret that I have to step down as a Board member of Oxford BioMedica as a result of my appointment as CEO of uniQure. Oxford BioMedica has an outstanding position as a world-leader in gene and cell-therapy. The Company has an excellent business model well balanced by an exciting pipeline of wholly owned products, sought-after IP and third party manufacturing and process development. With its strong management team, I have no doubt that Oxford BioMedica is en route to long-term success and I have greatly enjoyed working with the team. I step down from my role feeling I leave the Company in an extremely strong position."
Oxford BioMedica’s Chairman*, Nick Rodgers, said: “Dan has made a valuable contribution to Oxford BioMedica. We thank him for his input and wish him well for the future.”
*Oxford BioMedica announced on 15 December 2015 that Lorenzo Tallarigo (experience includes: Intercept Pharmaceuticals, Genextra and Eli Lilly) has been appointed as Non-Executive Chairman of the Group and will join on 1 February 2016.
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips
Tel: +44 (0)20 3709 5700